D'Souza V, Bhogal P, Njue A. Impact of the innovative licensing and access pathway (ILAP) designation on regulatory and health technology assessment (HTA) outcomes. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S312. doi: 10..1016/j.jval.2024.10.1623
Leonard C, Bhogal P, Menon AP, Ling C, Mordin M. HTA requirements for medical technologies in Spain. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S494. doi: 10.1016/j.jval.2024.10.2513
Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L. HTA requirements for medical technologies in Canada. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S286. doi: 10.1016/j.jval.2024.03.1564
Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L. What is the medical technology HTA process in Japan? Poster presented at the ISPOR 2024; May 6, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S284. doi: 10.1016/j.jval.2024.03.1554